Overview of Uphamol 650

Property	Description
Active Ingredient	Acetaminophen (Paracetamol)
Form	Tablet (650 mg strength)
Pharmacological Class	Analgesic, Antipyretic
General Purpose	Relief of pain and fever
Origin	Synthetic organic compound

What Type of Medicine is Uphamol 650?

Uphamol 650 is a single-ingredient medicine classified as an analgesic (pain-relieving) and antipyretic (fever-reducing) agent. Its chemical structure places it in the Para-aminophenol derivative group. This synthetic organic compound is widely used, and Acetaminophen is recognized for its effectiveness in reducing fever. This analgesic antipyretic action is clinically recognized for its role in the management of common symptoms, such as the aches associated with general malaise or the elevated temperatures of a mild fever.

The medicine's primary role is defined by its ability to modulate the body's central mechanisms for pain and temperature control. Unlike Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which primarily work by targeting inflammation throughout the body, Acetaminophen exerts minimal anti-inflammatory effect, focusing instead on central relief.

Composition and Form: The 650 mg Acetaminophen Tablet

The active ingredient in Uphamol 650 is Acetaminophen, chemically synonymous with Paracetamol. The medicine is presented in the dosage form of a tablet, designed for oral administration. Uphamol 650 is often available as an over-the-counter (OTC) product, depending on local regulatory requirements in its primary markets.

The 650 mg strength is the distinguishing feature of this preparation, serving as a high-concentration unit dose within the Acetaminophen family. The composition is strictly monotherapy, meaning it contains only Acetaminophen along with the solid pharmaceutical excipients needed to form the tablet structure. Acetaminophen is recognized for its analgesic properties, acting to help ease discomfort by influencing the body's pain response centrally.

How Does Acetaminophen Provide Pain and Fever Relief?

The pain-relieving and fever-reducing effects of Uphamol 650 are achieved by acting on the Central Nervous System. The compound targets the heat-regulating center in the hypothalamus, promoting heat dissipation and helping the body to normalize body temperature. Simultaneously, it raises the pain perception threshold, helping to lessen the sensation of pain. This central mode of action is key to its general purpose.

Regulatory References

Therapeutic Uses of Uphamol 650

Uphamol 650 (Acetaminophen 650 mg) is considered relevant in contexts marked by increased discomfort or tension, providing short-term supportive relief to manage symptoms that interfere with daily functioning. Such application is appropriate when supportive symptom management is indicated.

The medication is commonly used for managing symptoms related to physical discomfort such as tension headaches, backache, muscular aches, toothache, and menstrual cramps. It is also applied in clinical settings marked by elevated body temperature (fever) and generalized body aches during acute episodes of the common cold or influenza. This application supports the patient during difficult episodes by easing distress.

“Uphamol 650 is relevant in contexts involving heightened systemic burden and is used when short-term symptomatic assistance is needed.”

Quick Fact: Relief for Episodic Pain and Fever The medication is relevant for easing symptoms related to physical discomfort and is commonly used when symptoms linked to temporary physiological imbalance, such as fever, become more noticeable. This provides support that contributes to easing the overall symptom load.

Regulatory References

NIH MedlinePlus Drug Information on Acetaminophen

Eligibility and Restrictions for Use

Who Can and Cannot Use Uphamol 650?

This section outlines the official population eligibility rules for Uphamol 650 (Acetaminophen 650 mg), as documented by governmental regulatory authorities.

Contraindicated Populations (Must Not Use) Uphamol 650 is formally contraindicated for patients with a known hypersensitivity or allergy to acetaminophen (paracetamol) or any component of the tablet. Use is also prohibited in individuals with severe active liver disease or severe hepatic impairment. Furthermore, concurrent use with any other medicine containing acetaminophen is strictly prohibited to prevent exceeding regulatory dose limits.

Populations with Restricted or Conditional Eligibility The medicine should be used with special caution in patients diagnosed with mild hepatic impairment, severe renal impairment (kidney function le 30 mL/min), chronic malnutrition, dehydration, or chronic alcoholism. These conditions may require professional supervision and limit total daily intake.

Age-Based Eligibility Adults and adolescents are the standard eligible populations. The 650 mg strength is generally not recommended for children under 12 years of age.

Pregnancy and Lactation Pregnant individuals are eligible for use if clinically needed, but regulatory guidance mandates the use of the lowest effective dose for the shortest possible duration. The medicine is considered compatible with breastfeeding when used at therapeutic doses.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory information emphasizes constraints related to co-administration with specific medicinal product categories and substances.

Do Not Combine

It is officially required to not use Uphamol 650 (Paracetamol/Acetaminophen) concurrently with any other product that contains Paracetamol/Acetaminophen, as this significantly increases the risk of severe liver injury.

Interactions with Specific Product Classes

Category	Practical Constraint Based on Official Documentation
Anticoagulants (e.g., Warfarin, other Coumarins)	Concomitant use requires medical consultation and INR monitoring, as the drug may increase the effect of the anticoagulant.
Enzyme Inducers (e.g., Phenytoin, Barbiturates, Carbamazepine)	Caution is required, as these drugs may increase the formation of the drug's toxic metabolite.
Gastroprokinetics (e.g., Metoclopramide, Domperidone)	These agents may increase the rate of absorption of Uphamol 650.
Uricosurics (e.g., Probenecid)	These agents may inhibit the drug's excretion, potentially requiring dosage adjustment based on medical advice.
Bile Acid Sequestrants (e.g., Cholestyramine)	These agents may reduce the rate and extent of absorption, requiring consideration of administration timing.

Interaction with Alcohol

Official warnings state that the risk of severe liver damage is substantially increased in individuals who regularly consume three (3) or more alcoholic drinks every day. This combination is strongly advised against.

Mechanism of Action

Central Targeting of Prostaglandin Production

Uphamol 650's active substance, paracetamol, primarily acts within the central nervous system (CNS). Its mechanism involves the inhibition of specific Cyclooxygenase (COX) enzymes, particularly within the brain and spinal cord. This interaction suppresses the enzymatic conversion of arachidonic acid, thereby reducing the synthesis and release of prostaglandins ( PGE2). Prostaglandins act as key mediators within central pain and thermoregulatory pathways. This targeted suppression of the prostaglandin synthesis cascade modulates central pain signaling and the body's thermoregulatory set-point.

Modulation of Descending Neural Pathways

Beyond enzyme inhibition, the drug engages secondary mechanisms that influence endogenous signaling. This includes interaction with the descending serotonergic pathway and influence on systems such as the endocannabinoid system via its metabolite, AM404. These complementary actions modulate key pathways associated with heightened physiological responses and influence descending pain signaling within the CNS.

Dosage and Administration Information

The administration of Uphamol 650 (Acetaminophen 650 mg) follows established protocols for its use as an oral analgesic and antipyretic agent. The 650 mg strength is typically classified as an Extended-Release (ER) or Modified-Release tablet, which dictates its structured usage pattern.

Official Administration Guidelines

Feature	Official Usage Protocol
Primary Route	Oral administration of the tablet.
Dosing Schedule	The standard adult dose is 1300 mg (two 650 mg tablets), which is administered every 8 hours.
Maximum Daily Limit	The total intake from all acetaminophen-containing products must not exceed 3900 mg (six 650 mg tablets) in a 24-hour period.
Tablet Integrity	The tablets are to be swallowed whole with water. Crushing, chewing, splitting, or dissolving the tablet is avoided to maintain the integrity of the controlled release mechanism.
Timing	The dose may be administered with or without food.
Duration of Use	Usage is restricted to short-term symptomatic relief: no more than 10 days for pain and no more than 3 days for fever without professional guidance.
Age Restriction	This specific 650 mg dosage strength is not intended for use in children under 12 years of age.

The administration protocol involves adherence to a minimum 8-hour interval between doses to prevent systemic accumulation. Furthermore, the requirement to calculate total acetaminophen from all possible sources is a key procedural consideration in its overall use.

Recent Clinical Evidence

Evidence for use in Acute Mild-to-Moderate Pain

Research has explored outcomes related to physical discomfort through short-term Randomized Controlled Trials (RCTs) and systematic reviews, primarily in adult populations. These studies monitored patient-reported pain assessments over short intervals, often comparing findings to a placebo. However, the applicability of specific findings to the 650 mg dose across all acute pain types is limited, as many large trials focus on a higher 1000 mg dose.

Evidence for use in Fever Management (Antipyresis)

The evidence includes older RCTs and modern Meta-analyses that monitored physiological strain and measured changes in body temperature in both adult and pediatric populations. Studies describe group patterns related to how quickly temperature change was observed. Certainty remains low in some areas because the evidence quality varies across studies, with some reviews noting modest sample sizes or methodological challenges in older trials.

Evidence for use in Chronic Musculoskeletal Pain

The research explored symptomatic relief in conditions marked by functional limitations, such as osteoarthritis (OA) of the hip or knee, using intermediate-term controlled trials. Trials reported measured outcomes related to physical discomfort over several weeks. Research notes that the reported size of the measured changes for OA has been described as modest. Conversely, research on acute low back pain indicates that large-scale trial data show patterns related to no measured difference in recovery or pain scores compared to a placebo.

Research Gaps and Uncertainty

Long-term effects are not fully established for continuous daily use, as follow-up durations were limited to the short-to-intermediate trial periods (typically less than three months). Comparative evidence is lacking for the 650 mg dose against placebo in certain acute contexts. Additionally, data for special populations, such as specific subgroups defined by comorbidities, remain insufficient, and overall evidence quality varies across certain indications.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Uphamol 650 (FAQ)

Q: How long can the pain relief from Uphamol 650 be expected to last?

The 650 mg tablet is an extended-release formula designed for structured use. This structure typically involves administering the medicine every 8 hours to maintain relief. Official information indicates that the fever-reducing effect is expected to last for at least 6 hours.

Q: How long does it usually take for Uphamol 650 to start working?

Clinical guidance describes that the pain-relieving effects of oral paracetamol generally begin to be noticed approximately 30 minutes after administration. This timeline reflects the period needed for the medicine to be absorbed and start working in the central nervous system.

Q: What are the signs of taking too much Uphamol 650?

In cases of acute overdose, initial symptoms within the first 24 hours can include mild nausea and vomiting, although some individuals may have no symptoms. Later (1 to 3 days), signs of developing liver injury may present, such as pain or tenderness in the upper right side of the abdomen. The risk of severe liver damage is the primary safety constraint of this medicine.

Q: What should be considered when using Uphamol 650 for a long period of time?

Regulatory documents describe limits on the duration of use, such as no more than 10 days for pain relief, unless professional guidance is obtained. The risk of kidney damage is formally associated with the prolonged or habitual use of high doses of paracetamol, according to official safety information.

Q: Is Uphamol 650 generally considered appropriate for use while breastfeeding?

Official regulatory guidance indicates that Uphamol 650 is generally considered compatible with breastfeeding when used at therapeutic doses. Studies have shown that only very small amounts of the active ingredient pass into breast milk, and no negative effects have been reported in infants.

Q: What foods or supplements are described as potentially interacting with Uphamol 650?

Official warnings emphasize a substantially increased risk of severe liver damage for individuals who regularly consume three or more alcoholic drinks every day while using the product. This combination is cautioned against in official regulatory warnings.

Q: Is Uphamol 650 considered gentle on the stomach?

Uphamol 650 is not classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). The medicine is permitted to be administered with or without food. Official product information notes that, unlike NSAIDs, it exerts minimal anti-inflammatory effects.

Q: Does Uphamol 650 help with inflammation, or only pain and fever?

Uphamol 650 is officially classified as an analgesic (pain reliever) and antipyretic (fever reducer). Its primary function involves acting on the central nervous system to reduce pain and fever. Official documents describe the medicine as exerting a minimal anti-inflammatory effect.

Q: Are skin reactions a recognized side effect of the medicine in Uphamol 650?

Yes, skin reactions are a recognized possibility. Official regulatory documentation cites 'Skin and Subcutaneous Tissue disorders' and specifically documents the risk of rare, but very serious, skin reactions known as Severe Cutaneous Adverse Reactions (SCARs).

Q: Does taking the active ingredient in Uphamol 650 commonly make a person feel sleepy?

The active ingredient in Uphamol 650, paracetamol, is not classified as a sedative and does not directly cause drowsiness. Official information clarifies that any reported sleepiness is usually associated with combination products that include other ingredients with sedative properties.

Q: Is there an interaction between Uphamol 650 and oral contraceptives?

Regulatory descriptions indicate that oral contraceptives may potentially affect the metabolism of the active ingredient, which could theoretically delay or decrease its effects. However, official information suggests this interaction often does not result in significant risk when the medicine is used at usual therapeutic doses.

Q: What should a patient do if they miss a scheduled dose of Uphamol 650?

Official administration guidelines mandate a strict minimum 8-hour interval between doses for the extended-release tablet. If a dose is missed, regulatory guidance instructs that the next dose should only be taken when it is needed, ensuring that the full 8-hour minimum interval has passed and the maximum daily limit is not exceeded.

Q: How can patients verify that they are not exceeding the maximum recommended daily amount of paracetamol from multiple products?

The regulatory protocol requires calculating the total intake from all acetaminophen-containing products against the stated maximum daily limit of 3900 mg. The process involves checking the label of every medicine used to identify and sum up the total milligrams of the active ingredient taken in a 24-hour period.

How should Uphamol 650 be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents mandate specific storage and disposal protocols to maintain the stability and safety of Uphamol 650 (Paracetamol 650 mg).

Scope Item	Official Regulatory Requirement
Storage Temperature	Store the product below 30 C; do not refrigerate or freeze.
Protection	Keep the medicine in a dry, cool place and protected from light and moisture.
Container Rule	Must be kept in the original package with the container tightly closed.
Child Safety	Keep out of the sight and reach of children at all times.
Disposal Rule	Unused or expired product must be disposed of in accordance with local requirements; do not throw into wastewater or household waste.

The official profile dictates that stability is preserved when the medicine is stored under 30 C, away from heat and light. Disposal must strictly adhere to local regulatory and environmental standards.

Component	Regulatory Statement
Key adverse reaction categories	Hepatotoxicity (liver damage), severe hypersensitivity reactions (including anaphylaxis), and specific hematological events (blood disorders).
Frequency classification	Serious events (e.g., severe skin reactions, anaphylaxis, certain blood dyscrasias) are generally classified as Rare or Very Rare in official labeling. Many general adverse effects may be listed with Frequency Not Known.
System-organ classes involved	Hepatobiliary disorders, Skin and Subcutaneous Tissue disorders, Blood and Lymphatic System disorders, and Immune System disorders are cited in regulatory documentation.
Serious adverse reactions	Severe liver damage/failure (hepatic necrosis), Severe Cutaneous Adverse Reactions (SCARs) including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Anaphylaxis are officially documented.

Feature	Official Regulatory Finding
Documented Overdose Presentations	Initial manifestations may include nausea, vomiting, anorexia, diaphoresis, pallor, and general malaise. These often precede the delayed onset of severe toxicity.
Physiological Systems Affected	Primary severe toxicity affects the Hepatic system, potentially leading to acute liver failure. Other systems involved include CNS and Renal.
Population-Specific Notes	Increased susceptibility to severe toxicity is noted in individuals with pre-existing hepatic impairment, chronic alcohol use, and malnutrition.
When Immediate Medical Help Is Required	Immediate evaluation is required for all suspected exposures; contact emergency services right away, even if the individual feels well.

Classification	Official Regulatory Concept
Severity Classification	Overdose is classified as potentially fatal due to the risk of severe hepatic necrosis.
Overdose-Context Constraints	Management relies on the use of the specific antidote, N-acetylcysteine (NAC), and hospital monitoring of serum drug levels and liver function tests.

Uphamol 650